Navigation Links
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:6/9/2008

out the 24-hour study period, as compared to placebo.

About Symphony Allegro

In December 2006, Alexza entered into a collaboration with Symphony Capital LLC, a biotech-focused private equity firm. Under the terms of the agreement, Alexza and Symphony Capital established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a license to certain intellectual property rights for the selected product candidates. Through a purchase option, Alexza retains the exclusive right, but not the obligation, to acquire 100% of the equity of Symphony Allegro at specified prices during the term of the agreement. If Alexza chooses not to exercise the purchase option, Symphony Allegro retains the rights to the product candidates. The purchase option expires December 31, 2010.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... that it is appealing the judgment of the Regional Court ... that found the headgear of certain mask models ... invalidity challenges against various ResMed patents in major countries. Apex ... junk patents. ResMed filed the lawsuit with ...
(Date:7/29/2014)... 29, 2014  Ambit Biosciences (Nasdaq: AMBI ), ... drugs targeting unmet needs in oncology, autoimmune and inflammatory ... results after closing of the NASDAQ Global Market on ... call hosted by Michael Martino , president and ... place on the same day at 5:00 pm EDT ...
(Date:7/29/2014)... , July 29, 2014  The BioFusionary ... on developing a proprietary electromagnetic induction platform with ... into an agreement under which TBC will merge ... Limited (COT) in an all-stock transaction. ... initially trade on the Australian Stock Exchange under ...
Breaking Medicine Technology:Apex Continues Fighting Against Patents to Free Up Competition 2Ambit Biosciences To Announce Second Quarter 2014 Financial Results 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3
... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
(Date:7/29/2014)... 29, 2014 “Our years of ... homeowners fail to insulate their homes properly simply ... of preventing heat transfer and conduction,” Clean Crawls ... they’ve recently released an article explaining exactly how ... their energy bills. , To contact Clean Crawls ...
(Date:7/29/2014)... “Approximately 18% of our population suffers from allergies, ... Western Washington Medical Group says in their recently ... from allergies to seek medical attention. , “Billions of ... in the United States,” they continue. “Many people have ... themselves, rather than seeking the appropriate treatment.” , Fortunately, ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign ... absorb embarrassing odors in the office. PoofPad is a discrete ... a desk drawer. This compact packaging is designed for ease ... on the pad and poof away! , “We’ve all been ... someone appears out of nowhere. It’s embarrassing and unpleasant for ...
(Date:7/29/2014)... 29, 2014 Riverdale Urgent Care is ... do. Through their presence at local events, partnerships and ... more than just a medical service for the Riverdale ... money in support of Riverdale RiverFest and South Riverdale ... that features local musicians and entertainers, arts and crafts, ...
Breaking Medicine News(10 mins):Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3
... Regions Hospital,this week opens a new 16-bed inpatient ... the region -- with an innovative way of caring ... schedule,providing improved continuity and a better experience for patients., ... provide care for,patients once they arrive in the emergency ...
... Late-Stage and Marketed ... ... England, February 18 /PRNewswire/,-- EUSA Pharma Inc (,EUSA,), a transatlantic ... today,announced that it has out-licensed the exclusive world-wide rights to ...
... Cancer Society study of twelve types of cancer among ... were significantly more likely to present with advanced stage ... which appears in the March issue of The Lancet ... investigate insurance status and stage of diagnosis for a ...
... known to impair the cognitive health of people, but ... learning and memory problems. A new National Institutes ... increased levels of a stress hormone produced by the ... the region of the brain responsible for learning and ...
... District Hospital, Dar es Salaam, Tanzania, WASHINGTON, Feb. ... President, First Lady, my dear wife -- Mr.,President, welcome again ... you so much, again, for PEPFAR, the President,s,Emergency Plan for ... -- these two buildings, a,facility we just visited, and again, ...
... Wing, professor of psychiatry and human behavior at The Warren ... Weight Control & Diabetes Research Center at The Miriam Hospital, ... dieters who lose weight and keep the pounds off, have ... , Using new research findings, Wing will make her case ...
Cached Medicine News:Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 3Health News:Major study links insurance status to advanced stage in multiple cancers 2Health News:Stress hormone impacts memory, learning in diabetic rodents 2Health News:Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar 2Health News:Large changes needed to address global obesity epidemic 2
1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
Penicillin-Streptomycin-Glutamine (100X) liquid...
Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
Medicine Products: